{
  "id": 4955,
  "text": "3 Minion LE, Tewari KS.Cervical cancer - State of science: From angiogenesis blockade to checkpoint inhibition.Gynecol Oncol 2018; Mar;148(3):609-621.4 Chung HC, Schellens JH, Delord J-P, et al.Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 3 Minion LE, Tewari KS.Cervical cancer - State of science: From angiogenesis blockade to checkpoint inhibition.Gynecol Oncol 2018; Mar;148(3):609-621.4 Chung HC, Schellens JH, Delord J-P, et al.Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.\n\n<question>: ",
  "ChatGPT_response_0": "近年来，宫颈癌治疗领域取得了一些重要的进展和研究成果。例如，有关血管生成抑制和检查点抑制的研究已经引起了人们的关注。另外，一些临床研究显示，帕博利珠单抗（Pembrolizumab）在治疗晚期宫颈癌方面取得了一些积极的结果。这些研究为宫颈癌的治疗带来了新的希望与可能性。您可以关注最新的研究成果和临床试验，以了解目前宫颈癌治疗领域的最新进展。",
  "query": "最近有关于宫颈癌治疗方面的任何进展或研究吗？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 最近有关于宫颈癌治疗方面的任何进展或研究吗？\n\n<reference text>: 3 Minion LE, Tewari KS.Cervical cancer - State of science: From angiogenesis blockade to checkpoint inhibition.Gynecol Oncol 2018; Mar;148(3):609-621.4 Chung HC, Schellens JH, Delord J-P, et al.Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.\n\n<reply>: ",
  "response": "近年来，宫颈癌治疗领域取得了一些重要的进展和研究成果。例如，有关血管生成抑制和检查点抑制的研究已经引起了人们的关注。另外，一些临床研究显示，帕博利珠单抗（Pembrolizumab）在治疗晚期宫颈癌方面取得了一些积极的结果。这些研究为宫颈癌的治疗带来了新的希望与可能性。您可以关注最新的研究成果和临床试验，以了解目前宫颈癌治疗领域的最新进展。"
}